The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a selective neurotoxin which produces degeneration of the nigrostriatal bundles in the central nervous system of man and animals. In these areas of the brain are concentrated the receptor binding sites for [3H]MPTP. 1-Alkyl-4, 4-diphenylpiperidines displace [3H]MPTP from these binding sites with Ki values in the micromolar range. The t-butyl analogue in this class of substances, budipine, is a novel therapeutic agent for Parkinsonism whose mechanism has not yet been fully clarified. The affinity of budipine for the MPTP receptor binding site was determined as a Ki value of 2.2 microM. Other 4, 4-diphenylpiperidine derivatives such as 1-methyl-4, 4-diphenylpiperidine and 1-i-propyl-4, 4-diphenylpiperidine have substantially lower affinities. Monoamine oxidase inhibitors such as deprenyl, pargyline and harmaline have affinities to the MPTP receptors which parallel their affinity for the B type of monoamine oxidase (MAO B). This supports the theory that the MPTP receptor binding sites is identical with membrane bound MAO B.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001921:Brain / Q000378:metabolism; D008297:Male; D009498:Neurotoxins / Q000378:metabolism*; D010880:Piperidines / Q000378:metabolism; D011725:Pyridines / Q000378:metabolism*; D011726:Pyridinium Compounds / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D011917:Rats, Inbred Lew; D011950:Receptors, Cholinergic / Q000032:analysis*; D013574:Synaptosomes / Q000378:metabolism
D009498:Neurotoxins; D010880:Piperidines; D011725:Pyridines; D011726:Pyridinium Compounds; D011950:Receptors, Cholinergic; C016695:prodipin; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C026710:budipine; D015655:1-Methyl-4-phenylpyridinium